Article
Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study).
BMC cancer - 19 Mar 2022
Zhang Bo, Shi Chunlei, Gao Zhiqiang, Zhong Hua, Xiong Liwen, Gu Aiqin, Wang Weimin, Chu Tianqing, Zhang Wei, Wang Huimin, Zhang Xueyan, Zhong Runbo, Han Baohui
Abstract excerpt
BACKGROUND: Dacomitinib is a second-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). ARCHER-1050 showed that this agent can improve progression-free survival and overall survival in advanced non-small cell lung cancer patients with sensitive EGFR mutation compared to gefitinib. However, it is unclear whether dacomitinib is effective in patients with sensitizing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.